Bindarit: An anti-inflammatory small molecule that modulates the NFκB pathway

Cell Cycle

Volumn 11, Issue 1, 2012, Pages 159-169

  Mora, Eugenio ^a   Guglielmotti, Angelo ^b   Biondi, Giuseppe ^b   Sassone Corsi, Paolo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

Bindarit; IL 12 p40; Inflammation; Lipopolysaccharide; Macrophages; MCP 1; NF B

Indexed keywords

BINDARIT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P50; SYNAPTOTAGMIN I;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CYTOKINE PRODUCTION; DNA BINDING; DOWN REGULATION; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; NONHUMAN; PANCREATITIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84855643283     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.1.18559     Document Type: Article

References (64)

1. Baeuerle PA, Henkel T. Function and activation of NFkappaB in the immune system. Annu Rev Immunol 1994; 12:141-79; PMID:8011280; http://dx.doi.org/10. 1146/annurev.iy.12.040194.001041.
2. Sun XF, Zhang H. NFκB and NFκBI polymorphisms in relation to susceptibility of tumor and other diseases. Histol Histopathol 2007; 22:1387-98; PMID:17701919.
3. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010; 10:369-73; PMID:20455855; http://dx.doi.org/10.2174/ 156652410791316968.
4. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway. Cell Cycle 2011; 10:2206-14; PMID:21623171; http://dx.doi.org/10.4161/cc.10.13.16348.
5. Hayden MS, Ghosh S. Signaling to NFkappaB. Genes Dev 2004; 18:2195-224; PMID:15371334; http://dx.doi.org/10.1101/gad.1228704.
6. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NFkappaB. Annu Rev Cell Biol 1994; 10:405-55; PMID:7888182; http://dx.doi.org/ 10.1146/annurev.cb.10.110194.002201.
7. Pahl HL. Activators and target genes of Rel/NFkappaB transcription factors. Oncogene 1999; 18:6853-66; PMID:10602461; http://dx.doi.org/10.1038/sj. onc.1203239.
8. Ghosh S, Karin M. Missing pieces in the NFκB puzzle. Cell 2002; 109:81-96; PMID:11983155; http://dx.doi.org/10.1016/S0092-8674(02)00703-1.
9. Bonizzi G, Karin M. The two NFκB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25:280-8; PMID:15145317; http://dx.doi.org/10.1016/j.it.2004.03.008.
10. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factorα and lymphotoxinß receptor activation. J Biol Chem 2003; 278:23278-84; PMID:12709443; http://dx.doi.org/10.1074/jbc.M300106200.
11. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NFκB2 in maturing B cells. Nat Immunol 2002; 3:958-65; PMID:12352969; http://dx.doi.org/10.1038/ni842.
12. Dejardin E. The alternative NFκB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72:1161-79; PMID:16970925; http://dx.doi.org/10.1016/j.bcp.2006.08.007.
13. Mihalcik SA, Tschumper RC, Jelinek DF. Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle 2010; 9:4884-92; PMID:21099364; http://dx.doi.org/10.4161/cc.9.24.14156.
14. Guglielmotti A, Silvestrini B, Saso L, Zwain I, Cheng CY. Chronic inflammatory response in the rat can be blocked by bindarit. Biochem Mol Biol Int 1993; 29:747-56; PMID:7683947.
15. Guglielmotti A, D'Onofrio E, Coletta I, Aquilini L, Milanese C, Pinza M. Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNFalpha production. Inflamm Res 2002; 51:252-8; PMID:12056513; http://dx.doi.org/10.1007/PL00000301.
16. Ialenti A, Grassia G, Gordon P, Maddaluno M, Di Lauro MV, Baker AH, et al. Inhibition of In-Stent Stenosis by Oral Administration of Bindarit in Porcine Coronary Arteries. Arterioscler Thromb Vasc Biol 2011; 31:2448-54; PMID:21852559; http://dx.doi.org/10.1161/ATVBAHA.111.230078.
17. Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998; 53:726-34; PMID:9507220; http://dx.doi.org/10.1046/j.1523-1755.1998.00804.x.
18. Ramnath RD, Ng SW, Guglielmotti A, Bhatia M. Role of MCP-1 in endotoxemia and sepsis. Int Immunopharmacol 2008; 8:810-8; PMID:18442784; http://dx.doi.org/10.1016/j.intimp.2008.01.033.
19. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224:93-100; PMID:20681057; http://dx.doi.org/10.1016/j. jneuroim.2010.05.010.
20. Lloyd CM, Dorf ME, Proydfoot A, Salant DJ, Gutierrez-Ramos JC. Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. J Leukoc Biol 1997; 62:676; PMID:9365123.
21. Luster AD, Rothenberg ME. Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol 1997; 62:620; PMID:9365117.
22. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994; 15:127; PMID:8172645; http://dx.doi.org/10.1016/0167- 5699(94)90156-2.
23. Jia T, Serbina NV, Brandl K, Zhong MX, Leiner IM, Charo IF, et al. Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J Immunol 2008; 180:6846-53; PMID:18453605.
24. Van Damme J, Proost P, Lenaerts JP, Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992; 176:59-65; PMID:1613466; http://dx.doi.org/10.1084/jem.176.1.59.
25. Ping D, Boekhoudt GH, Rogers EM, Boss JM. Nuclear factor-kappaB p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999; 162:727-34; PMID:9916692.
26. Ping D, Jones PL, Boss JM. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the MCP-1/JE gene. Immunity 1996; 4:455-69; PMID:8630731; http://dx.doi.org/10.1016/S1074-7613(00)80412-4.
27. Boekhoudt GH, Guo, Beresford GW, Boss JM. Communication between NFkappaB and Sp1 controls histone acetylation within the proximal promoter of the monocyte chemoattractant protein 1 gene. J Immunol 2003; 170:4139-47; PMID:12682245.
28. Ping D, Boekhoudt G, Zhang F, Morris A, Philipsen S, Warren ST, et al. Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem 2000; 275:1708-14; PMID:10636866; http://dx.doi.org/10.1074/jbc.275.3.1708.
29. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80; PMID:11477402; http://dx.doi.org/10.1038/90609.
30. Takeuchi O, Hemmi H, Akira S. Interferon response induced by Toll-like receptor signaling. J Endotoxin Res 2004; 10:252-6; PMID:15373970.
31. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216; PMID:11861602; http://dx.doi.org/10.1146/annurev.immunol.20. 083001.084359.
32. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18:3-9; PMID:16343886; http://dx.doi.org/10. 1016/j.coi.2005.11.012.
33. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42:145-51; PMID:18304834; http://dx.doi.org/10.1016/j.cyto.2008.01.006.
34. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300:1524-5; PMID:12791976; http://dx.doi.org/10.1126/science.1085536.
35. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80; PMID:11477402; http://dx.doi.org/10.1038/90609.
36. Schmitz ML, Bacher S, Kracht M. Ikappa B-independent control of NFkappaB activity by modulatory phosphorylations. Trends Biochem Sci 2001; 26:186-90; PMID:11246025; http://dx.doi.org/10.1016/S0968-0004(00)01753-9.
37. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, BucκBinder L, et al. NFkappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005; 25:7966-75; PMID:16135789; http://dx.doi.org/10.1128/MCB.25.18.7966-7975. 2005.
38. Teferedegne B, Green MR, Guo Z, Boss JM. Mechanism of action of a distal NFkappaB-dependent enhancer. Mol Cell Biol 2006; 26:5759-70; PMID:16847329; http://dx.doi.org/10.1128/MCB.00271-06.
39. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, et al. NFkappaB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994; 153:2052-63; PMID:8051410.
40. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. Regulation of interleukin 12 p40 expression through an NFkappaB half-site. Mol Cell Biol 1995; 15:5258-67; PMID:7565674.
41. Sironi M, Guglielmotti A, Polentarutti N, Fioretti F, Milanese C, Romano M, et al. A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1. Eur Cytokine Netw 1999; 10:437-42; PMID:10477401.
42. Mirolo M, Fabbri M, Sironi M, Vecchi A, Guglielmotti A, Mangano G, et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 2008; 19:119-22; PMID:18775807.
43. Akira S, Uematsu O. Takeuchi. Pathogen recognition and innate immunity. Cell 2006; 124:783-801; PMID:16497588; http://dx.doi.org/10.1016/j.cell.2006.02. 015.
44. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22:891-928; PMID:15032599; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104543.
45. DeVries ME, Kelvin AA, Xu L, Ran L, Robinson J, Kelvin DJ. Defining the origins and evolution of the chemokine/chemokine receptor system. J Immunol 2006; 176:401-15; PMID:16365434.
46. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006; 7:243; PMID:17201934; http://dx.doi.org/10.1186/gb-2006-7-12-243.
47. Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS. The regulation and biological activity of interleukin 12. Leuk Lymphoma 1998; 29:427-38; PMID:9643557; http://dx.doi.org/10.3109/10428199809050903.
48. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13:4677-85; PMID:17699845; http://dx.doi.org/10.1158/1078-0432.CCR-07- 0776.
49. Kim S, Chung EY, Ma X. Immunological consequences of macrophage-mediated clearance of apoptotic cells. Cell Cycle 2005; 4:231-4; PMID:15655362; http://dx.doi.org/10.4161/cc.4.2.1428.
50. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA 1985; 82:5328-31; PMID:2410919; http://dx.doi.org/10.1073/pnas.82.16.5328.
51. Sommers CD, Thompson JM, Guzova JA, Bonar SL, Rader RK, Mathialagan S, et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 2009; 330:377-88; PMID:19478133; http://dx.doi.org/10.1124/ jpet.108.147538.
52. Nowak DE, Tian B, Brasier AR. Two-step cross-linking method for identification of NFkappaB gene network by chromatin immunoprecipitation. Biotechniques 2005; 39:715-25; PMID:16315372; http://dx.doi.org/10.2144/ 000112014.
53. Saccani S, Pantano S, Natoli G. Two waves of nuclear factor kappaB recruitment to target promoters. J Exp Med 2001; 193:1351-9; PMID:11413190; http://dx.doi.org/10.1084/jem.193.12.1351.
54. Grimaldi B, Nakahata Y, Sahar S, Kaluzova M, Gauthier D, Pham K, et al. Chromatin remodeling and circadian control: master regulator CLOCK is an enzyme. Cold Spring Harb Symp Quant Biol 2007; 72:105-12; PMID:18419267; http://dx.doi.org/10.1101/sqb.2007.72.049.
55. Cardone L, Hirayama J, Giordano F, Tamaru T, Palvimo JJ, Sassone-Corsi P. Circadian clock control by SUMOylation of BMAL1. Science 2005; 309:1390-4; PMID:16109848; http://dx.doi.org/10.1126/science.1110689.
56. Nóvak EM, Dantas KC, Charbel CE, Bydlowski SP. Association of hepatic nuclear factor-4 in the apolipoprotein B promoter: a preliminary report. Braz J Med Biol Res 1998; 31:1405-8; PMID:9921275.
57. Hosoe S, Ogura T, Hayashi S, Komuta K, Ikeda T, Shirasaka T, et al. Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor. Cancer Immunol Immunother 1989; 28:116-22; PMID:2645051; http://dx.doi.org/10.1007/BF00199111.
58. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 1998; 95:4333-7; PMID:9539737; http://dx.doi.org/10.1073/pnas.95.8.4333.
59. Srivastava GK, de Larrea GZ. UVB-induced murine bone marrow derived macrophages and apoptosis. Immunol Invest 2008; 37:293-313; PMID:18569072; http://dx.doi.org/10.1080/08820130802083689.
60. Waheed A, Shadduck RK. Purification and properties of L cell-derived colony-stimulating factor. J Lab Clin Med 1979; 94:180-93; PMID:313966.
61. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappaB. Proc Natl Acad Sci USA 1989; 86:2336-40; PMID:2494664; http://dx.doi.org/10.1073/pnas.86.7.2336.
62. Brou C, Chaudhary S, Davidson I, Lutz Y, Wu J, Egly JM, et al. Distinct TFIID complexes mediate the effect of different transcriptional activators. EMBO J 1993; 12:489-99; PMID:8440239.
63. Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J, Amin RH, et al. PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab 2010; 12:509-20; PMID:21035761; http://dx.doi.org/10.1016/j.cmet.2010.10.005.
64. Piehler AP, Grimholt RM, Ovstebø R, Berg JP. Gene expression results in lipopolysaccharide-stimulated monocytes depend significantly on the choice of reference genes. BMC Immunol 2010; 11:21; PMID:20441576; http://dx.doi.org/10.1186/1471-2172-11-21.